DNTH Stock Analysis: Buy, Sell, or Hold?
DNTH - Dianthus Therapeutics, Inc. Common Stock
$79.45
-1.68 (-2.07%)
▼
5d:
+0.16%
30d:
+43.96%
90d:
+89.94%
BUY
MODERATE Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 11, 2026
Smart Money Distribution
DNTH is up 17.4% this week, but smart money is buying puts. Top strike: $85 2026-04-17 with 3 OI. Put ratio: 88% View Scanner →
Strength: 10.0/10
Get Alerted When DNTH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: DNTH shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: DNTH shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: DNTH is currently trading at $79.45, which is considered slightly high relative to its 30-day fair value range of $54.20 to $81.36.
Technical Outlook: Technically, DNTH is in a strong uptrend. Immediate support is located at $75.50, while resistance sits at $84.75.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $127.75 (+57.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DNTH is in a strong uptrend. Immediate support is located at $75.50, while resistance sits at $84.75.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $127.75 (+57.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$54.20 -
$81.36
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
66.8%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 57.5% below Wall St target ($127.75)
Fair Price Analysis
30-Day Fair Range
$54.20 -
$81.36
Current vs Fair Value
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$75.50
Resistance Level
$84.75
Current Trend
Strong Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-15.86
Wall Street Target
$127.75
(+57.5%)
Revenue Growth (YoY)
-78.6%
Share & Embed Analysis
Last updated: March 30, 2026 4:51 PM ET
Data refreshes hourly during market hours. Next update: 5:51 PM
Data refreshes hourly during market hours. Next update: 5:51 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DNTH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Edward Carr
SELL
43682 shares
2026-03-12
Marino Garcia
SELL
122918 shares
2026-03-12
Simrat Randhawa
SELL
33830 shares
2026-03-12
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 62 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 53 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 61 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 58 HOLD |
Advanced DNTH Option Strategies
Professional options setups generated by AI based on today's DNTH price and gamma walls.
